The Galien Forum USA 2019

PANEL
2

Co-Chairs
Joel S. Marcus
Executive Chairman & Founder
Alexandria Real
Estate Equities, Inc./
Alexandria Venture Investments;
Co-Founder
Alexandria Summit

Lynne Zydowsky, PhD
Chief Science Officer
Alexandria Real
Estate Equities, Inc./
Alexandria Venture Investments;
President and Co-Founder
Alexandria Summit

Panelists
David R. Epstein, MBA
Executive Partner
Flagship Pioneering

Joshua J. Ofman, MD, MSHS
Chief of Corporate Strategy
and External Affairs
GRAIL

David Schenkein, MD
General Partner, Google Ventures;
Executive Chairman of the Board
& Former Chief Executive Officer
,
Agios Pharmaceuticals

Panel Intro

Sponsored by

Can disruptive innovation positively impact healthcare costs?


Joel S. Marcus
Executive Chairman & Founder
Alexandria Real Estate Equities, Inc./
Alexandria Venture Investments;
Co-Founder, Alexandria Summit

Joel S. Marcus is the Executive Chairman and Founder of Alexandria Real Estate Equities, Inc. (NYSE:ARE), an urban office REIT and the first and longest-tenured owner, operator, and developer of collaborative life science, technology, and agtech campuses in AAA innovation cluster locations, including Greater Boston, San Francisco, New York City, San Diego, and Seattle. Pioneering the life science real estate niche, Mr. Marcus co-founded Alexandria in 1994 as a garage startup with $19 million in Series A capital. As CEO from March 1997 to April 2018, he led its growth into an S&P 500 company with a total market capitalization of $18 billion.

In 1996, Mr. Marcus founded Alexandria Venture Investments, the company’s venture capital arm, to provide strategic investment capital to transformative life science, technology, and agtech companies. The Alexandria Summit, a neutral, interactive platform, co-founded in 2011 by Mr. Marcus, Dr. Lynne Zydowsky and Ms. Deeda Blair convenes a diverse group of visionary stakeholders for transformative discussions and collaborations that help drive the discovery and development of novel, cost-effective therapies; shape policy to advance innovation that saves lives and cures disease; and inspire new ways of addressing the urgent need to transform our healthcare system.

He serves on the boards of Applied Therapeutics (NASDAQ:APLT), Intra-Cellular Therapies (NASDAQ:ITCI), MeiraGTx Holdings (NASDAQ:MGTX), Boragen Inc., Frequency Therapeutics,  the Foundation for the National Institutes of Health, MassBio, Scripps Research, the Emily Krzyzewski Center, the National September 11 Memorial & Museum, the Navy SEAL Foundation, the Partnership for New York City, and Robin Hood.


Lynne Zydowsky

Lynne Zydowsky, PhD
Chief Science Officer
Alexandria Real Estate Equities, Inc./
Alexandria Venture Investments;
President and Co-Founder, Alexandria Summit

Lynne Zydowsky, PhD, President and Co-Founder of the Alexandria Summit and Chief Science Officer of Alexandria Real Estate Equities, Inc./Alexandria Venture Investments, and President of Zydowsky Consultants, is an experienced executive in the life science industry who has been involved in the launching and building of several successful companies. With over 20 years of experience, she has played key roles in corporate development, operations, and finance. She is a long-standing advocate for biomedical research and the advancement of global health.

In 2003, Dr. Zydowsky founded Zydowsky Consultants, a consulting practice offering services to life science companies. Prior to that, Dr. Zydowsky was Co-Founder and Chief Operating Officer of Renovis, Inc. (now Evotec) and served as Vice President of Pharmaceutical Business Development at Exelixis, Inc. As part of their executive management teams, she contributed to the growth and development of both companies, which led to their initial public offerings.

The Alexandria Summit, a neutral, interactive platform, co-founded in 2011 by Mr. Joel Marcus, Dr. Zydowsky, and Ms. Deeda Blair, convenes a diverse group of visionary stakeholders for transformative discussions and collaborations that help drive the discovery and development of novel, cost-effective therapies; shape policy to advance innovation that saves lives and cures disease; and inspires new ways of addressing the urgent need to transform our healthcare system.

Dr. Zydowsky currently serves on the Board of Directors for the Reagan-Udall Foundation for the FDA (since October 2018) and Yumanity Therapeutics (since 2019), the Board of Trustees for Butler University (since September 2016), and the Discovery Council for Harvard Medical School (since August 2018). She serves as a Board Observer for OneFifteen, a non-profit healthcare ecosystem dedicated to the full and sustained recovery of people living with opioid addiction, on behalf of Alexandria Real Estate Equities, Inc. / Alexandria Venture Investments..

Dr. Zydowsky is also personally engaged in critical philanthropic efforts as a member of the West Coast Board for the international non-profit buildOn, an organization focused on breaking the cycle of poverty, illiteracy, and low expectations through its after-school programs for urban teens based on changing lives and communities through service locally and globally.

Dr. Zydowsky earned her PhD in Chemistry from The Ohio State University and was a National Institutes of Health postdoctoral fellow in the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. She has a Bachelor of Science degree in Pharmacy from Butler University.


David R. EpsteinDavid R. Epstein, MBA
Executive Partner
Flagship Pioneering

David R. Epstein is Executive Partner at Flagship Pioneering, Chairman of Axcella Health, Chairman of Rubius Therapeutics, and Chairman of Evelo Biosciences. Mr. Epstein is also a board member at International Flavors & Fragrances and Integral Health.

From early 2010 to mid-2016, he served as Chief Executive Officer of Novartis Pharmaceuticals, a division of Novartis AG. Previously, Mr. Epstein started and led Novartis’s Oncology and Molecular Diagnostic units. Under his leadership, the company’s oncology business grew to the second largest in the world.

Mr. Epstein has more than 25 years of extensive drug development, deal making, commercialization, and leadership experience on a global scale. Over the course of his career, he led the development and commercialization of over 30 new molecular entities, including major breakthroughs such as Glivec, Tasigna, Gilenya, Afinitor, Cosentyx, and Entresto. His teams developed three Prix Galien Award winners, and he has developed several CEOs. He was named by FierceBiotech as one of the “25 most influential people in biopharma.”

Early in his career, Mr. Epstein was an associate in the strategy practice of consulting firm Booz Allen Hamilton. He holds a BS in Pharmacy from the Rutgers College of Pharmacy (1984) and an MBA in Finance and Marketing from the Columbia University Graduate School of Business (1987).


Ofman-JoshJoshua J. Ofman, MD, MSHS
Chief of Corporate Strategy
and External Affairs
GRAIL

Josh Ofman, MD, MSHS, is Chief of Corporate Strategy and External Affairs at GRAIL. Dr. Ofman also serves on the Board of Directors of Cell BT, Inc., an immuno-therapy company focused on the discovery and development of innovative cancer therapeutics. Previously, Dr. Ofman spent more than 15 years at Amgen, where he most recently held the role of Senior Vice President, Global Health Policy. Prior to that, Dr. Ofman was a faculty member in the Department of Medicine and Health Services Research at the University of California, Los Angeles (UCLA) School of Medicine, Cedars-Sinai Medical Center, as well as Senior Vice President of Zynx Health Inc., a subsidiary of Cerner Corp. Dr. Ofman holds a BA in History and Philosophy of Science from the University of California, Berkeley, and an MD from the University of California, Irvine, School of Medicine. Dr. Ofman also has an MSHS from the UCLA School of Public Health.


David SchenkeinDavid Schenkein, MD
General Partner, Google Ventures;
Executive Chairman of the Board & Former Chief Executive Officer,
Agios Pharmaceuticals

David Schenkein, MD, is a General Partner at GV, where he co-leads the life science investment team. Previously, Dr. Schenkein spent ten years as Chief Executive Officer and a member of the board of directors at Agios Pharmaceuticals, where he remains as Executive Chairman.

Dr. Schenkein has been a hematologist and medical oncologist for 30 years. He currently serves as an Adjunct Attending Physician in Hematology at Tufts Medical Center. Prior to joining Agios, Dr. Schenkein was the Senior Vice President, Clinical Hematology/Oncology at Genentech, where he was responsible for numerous successful oncology drug approvals and leading the medical and scientific strategies for its BioOncology portfolio. While at Genentech, he served as an Adjunct Clinical Professor of Medical Oncology at Stanford University School of Medicine.

Prior to joining Genentech, he served as the Senior Vice President of Clinical Research at Millennium Pharmaceuticals, overseeing the clinical development and worldwide approval of Velcade, a first-in-class cancer therapy now approved to treat multiple myeloma and non-Hodgkin lymphoma. He serves on the board of directors of bluebird bio and Denali Therapeutics.

Dr. Schenkein holds a BA in Chemistry from Wesleyan University and an MD from the State University of New York Upstate Medical.